Daré Bioscience announces funding award to further the development of Ovaprene(TM) from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Stock Information for Dare Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dare Bioscience Inc.

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Dare? Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Dare? Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Dare? Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.